MaaT Pharma S.A.
PAR: MAAT.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Herve Affagard
- Employees
- 59
- Headquarters
- Lyon, France
- IPO year
- 2021
- Market cap
- €104.8M
- Website
- https://www.maatpharma.com
Loading MAAT…
Loading profile data…Frequently asked questions about MAAT
What does MaaT Pharma S.A. (MAAT.PA) do?
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033...
Where does MAAT.PA trade?
MaaT Pharma S.A. (MAAT.PA) trades on the Euronext Paris.
What sector is MAAT.PA in?
MaaT Pharma S.A. (MAAT.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MaaT Pharma S.A.?
Herve Affagard is the chief executive officer of MaaT Pharma S.A. (MAAT.PA).
Where is MaaT Pharma S.A. headquartered?
MaaT Pharma S.A. is headquartered in France.
Does MAAT.PA pay a dividend?
MaaT Pharma S.A. (MAAT.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MAAT.PA go public?
MaaT Pharma S.A. (MAAT.PA) completed its initial public offering in 2021.